News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Yan Leyfman: Are Immune Checkpoint Inhibitors Safe for Patients with Neurologic Autoimmune Disorders
Yan Leyfman
Jun 10, 2025, 05:11

Yan Leyfman: Are Immune Checkpoint Inhibitors Safe for Patients with Neurologic Autoimmune Disorders

Yan Leyfman, Co-founder and Executive Director of MedNews Week, posted on LinkedIn:

“Are Immune Checkpoint Inhibitors (ICIs) Safe for Patients with Neurologic Autoimmune Disorders (NAIDs)? A multicenter study of 135 cancer patients with NAIDs sheds light:
  • Myasthenia Gravis (MG): Highest risk — 67% had neurologic exacerbations, some severe or fatal.
  • Multiple Sclerosis (MS): 18% experienced flares — generally milder.
  •  Guillain-Barré (GBS): No exacerbations observed, but 1 fatal immune-related event.
  •  Survival Outcomes: No difference in PFS or OS across NAID groups.
Takeaway: ICIs may be viable for many with NAIDs, but caution is crucial, especially in MG.”

Title: Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders

Authors: Kylie Fletcher, Marc Machaalani, Razane El Hajj Chehade, Amin H. Nassar, Rashad Nawfal, Michael Manos, Alexander M. Menzies, Frank Aboubakar-Nana, Jessica C. Hassel, David J. Pinato, Alexandra Johnson, Anna C. Olsson-Brown, Matteo S. Carlino, Andrea Malgeri, Alessio Cortellini, Aditi Singh, Kaushal Parikh, So Yeon Kim, Abdul Rafeh Naqash, Georgina V. Long, Pavan Challa, Toni K. Choueiri, Elad Sharon, Shailee Shah, Douglas B. Johnson

Read the Full Article.

Yan Leyfman: Are Immune Checkpoint Inhibitors Safe for Patients with Neurologic Autoimmune Disorders

More posts featuring Yan Leyfman on OncoDaily.

Abdul Rafeh Naqash Aditi Singh Alessio Cortellini Alexander M. Menzies Alexandra Johnson Amin H. Nassar Andrea Malgeri Anna C. Olsson-Brown cancer David J. Pinato Douglas B Johnson Elad Sharon Frank Aboubakar-Nana Georgina V. Long Jessica C. Hassel Kaushal Parikh Kylie Fletcher Marc Machaalani Matteo S Carlino Michael Manos OncoDaily Oncology Pavan Challa Rashad Nawfal Razane El Hajj Chehade Shailee Shah So Yeon Kim Toni K. Choueiri Yan Leyfman
Special Coverage
Insight
Jun 10, 2025, 05:11
Yan Leyfman: Are Immune Checkpoint Inhibitors Safe for Patients with Neurologic Autoimmune Disorders
Blog
Jun 10, 2025, 04:55
Naveen Pemmaraju: Proud to be one of the featured lead authors for one of the five selected abstracts for the Plenary Session at ASCO
Blog
Jun 10, 2025, 04:48
M. Tezer Kutluk: Proud to contribute a chapter to the newly published book Cancer Systems and Control
Blog
Jun 10, 2025, 04:40
Jasmine Kamboj: Join the ASCO Community of Practice on Health Policy – Empower and Learn Together
Drugs
Jun 10, 2025, 03:46
Futibatinib (Lytgobi): Uses in Cancer, Side Effects, Dosage, Expectations, and More
Blog
Jun 10, 2025, 03:30
Herbert Loong: Discussing the Role of Selective RET Inhibitors in NSCLC
Blog
Jun 10, 2025, 02:43
Men's Health Month 2025: Closing the Empathy Gap
Positive
Jun 9, 2025, 20:00
Selwyn Vickers Congratulates the Graduates of the 2025 Class of the GSK Graduate School
Blog
Jun 9, 2025, 19:54
IARC/WHO Announces Webinar on Cancer Screening Challenges in Asia-Pacific
Career
Jun 9, 2025, 19:43
Philip Shabo: Proud to Welcome Dr. Dima Abdul Jabbar as the Director of the Burjeel Breast Center at BCI
Science
Jun 9, 2025, 19:40
Hung Trinh: An Ionizable Lipid Toolbox for RNA Delivery and the Rise of LNP-Based mRNA Vaccines
Blog
Jun 9, 2025, 19:32
AstraZeneca - What Could Happen When Policy Interventions Focus on Improved Detection and Treatment of CKD?